Medical Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305-5456, USA.
Hematol Oncol Clin North Am. 2013 Aug;27(4):751-65, viii. doi: 10.1016/j.hoc.2013.05.007.
ERBB2 gene amplification occurs in ∼20% of human breast cancers (BC) and is associated with an adverse clinical prognosis, indicating that it may be playing a critical role in disease pathogenesis. Therapeutic strategies targeting pathologic ERBB2 overexpression have revolutionized the diagnosis and treatment of BC. Indeed, humanized anti-ERBB2 antibodies, small molecule ERBB2 kinase inhibitors and ERBB2-targeting antibody-drug conjugates have proven safety and efficacy based upon evidence from randomized phase III clinical trials. Recent progress in targeting ERBB2 alteration will be reviewed, with focus on data that has informed changes in clinical practice for the treatment of BC.
ERBB2 基因扩增发生在约 20%的人类乳腺癌 (BC) 中，与不良临床预后相关，表明其可能在疾病发病机制中发挥关键作用。针对病理性 ERBB2 过表达的治疗策略彻底改变了 BC 的诊断和治疗。事实上，基于随机 III 期临床试验的证据，人源化抗 ERBB2 抗体、小分子 ERBB2 激酶抑制剂和 ERBB2 靶向抗体药物偶联物已被证明具有安全性和有效性。本文将回顾针对 ERBB2 改变的最新进展，重点关注为 BC 治疗改变临床实践提供信息的数据。
